Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | 12,128 | 8,485 |
| Cost of revenue | 4,372 | 3,353 |
| Gross profit | 7,756 | 5,132 |
| Research and development costs | 4,522 | 3,379 |
| Sales and marketing expenses | 6,715 | 3,834 |
| General and administrative expenses | 4,997 | 4,082 |
| Operating loss | (8,478) | (6,163) |
| Other income (expense): |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's R&D?
- ClearPoint Neuro (CLPT) reported R&D of $4.52M in Q1 2026.
- How has ClearPoint Neuro's R&D changed year-over-year?
- ClearPoint Neuro's R&D increased by 33.8% year-over-year, from $3.38M to $4.52M.
- What is the long-term trend for ClearPoint Neuro's R&D?
- Over 4 years (2021 to 2025), ClearPoint Neuro's R&D has grown at a 10.4% compound annual growth rate (CAGR), from $9.35M to $13.9M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about ClearPoint Neuro's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude